SCHEMBL4332906

SCHEMBL4332906

C=CCN(N=Cc1ccc(-c2ccc(Cl)cc2)o1)C(N)=S

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.49
WDR77 Q9BQA1 1/20 0.49
MAPT P10636 10/20 0.44
KDM4E B2RXH2 8/20 0.44
ALDH1A1 P00352 6/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MEN1 O00255 6/20 0.43
KMT2A Q03164 6/20 0.43
NPSR1 Q6W5P4 5/20 0.43
HPGD P15428 5/20 0.43
LMNA P02545 4/20 0.43
PKM P14618 1/20 0.43
ALOX12 P18054 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HTT P42858 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
TDP1 Q9NUW8 2/20 0.41
MAPK1 P28482 2/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4329307 0.85 MAPT (0.48) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL4329435 0.84 MAPT (0.58) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL4462859 0.79 PRMT5 (0.54) PRMT5WDR77MAPTKDM4EALDH1A1
SCHEMBL4332806 0.77 POLB (0.44) PRMT5WDR77MAPTKDM4EALDH1A1
SCHEMBL4329107 0.77 ALDH1A1 (0.45) PRMT5WDR77MAPTKDM4EALDH1A1
SCHEMBL4450066 0.75 PRMT5 (0.50) PRMT5WDR77MAPTKDM4EALDH1A1
SCHEMBL4455856 0.74 KMT2A (0.60) MAPTKDM4EALDH1A1L3MBTL1MEN1
SCHEMBL4455963 0.73 KDM4E (0.51) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL4341232 0.73 KMT2A (0.58) MAPTKDM4EALDH1A1L3MBTL1MEN1
SCHEMBL4341378 0.72 MAPT (0.48) MAPTKDM4EALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 PRMT5 4357/4885WDR77 3480/4885MAPT 3619/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 PRMT5 3764/4885WDR77 3201/4885MAPT 3876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.